Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award

Rhea-AI Filing Summary

Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.

Ironwood Pharmaceuticals’ principal accounting officer Ronald Silver received a stock-based compensation grant. He was awarded 163,934 shares of Class A Common Stock as restricted stock units, with no cash paid per share. The award vests in four equal annual installments. Following this grant, he directly holds 416,570 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Silver Ronald

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	163,934	$0.00	--

Holdings After Transaction: Class A Common Stock — 416,570 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silver Ronald

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/10/2026		A(1)		163,934	A	$0	416,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.

	/s/ Amir Vitale, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ironwood Pharmaceuticals (IRWD) report for Ronald Silver?

Ironwood Pharmaceuticals reported that Principal Accounting Officer Ronald Silver received a grant of 163,934 restricted stock units of Class A Common Stock. This was a stock-based compensation award, not an open-market purchase, and increased his directly held shares to 416,570.

Was Ronald Silver’s Form 4 transaction in IRWD stock a purchase or a grant?

The Form 4 shows a grant, not a purchase. Ronald Silver acquired 163,934 shares of Class A Common Stock through a restricted stock unit award with a per-share transaction price of $0.00, reflecting compensation rather than an open-market buy.

How does the restricted stock unit award to Ronald Silver vest at Ironwood (IRWD)?

The restricted stock unit award to Ronald Silver vests over four years. According to the footnote, 25% of the underlying Class A Common Stock shares vest on each approximate anniversary of the grant date, creating a gradual, time-based vesting schedule.

How many Ironwood (IRWD) shares does Ronald Silver own after this Form 4 transaction?

After the grant, Ronald Silver directly owns 416,570 shares of Ironwood Pharmaceuticals Class A Common Stock. This total reflects his holdings following the 163,934-share restricted stock unit award reported in the Form 4 filing.

What role does Ronald Silver hold at Ironwood Pharmaceuticals (IRWD) in this Form 4?

In this Form 4, Ronald Silver is identified as an officer of Ironwood Pharmaceuticals, serving as Principal Accounting Officer. The reported transaction reflects stock-based compensation associated with his executive role, rather than an outside investment trade.

Does the Form 4 for Ironwood (IRWD) mention any derivative securities for Ronald Silver?

The Form 4 data show no derivative transactions for Ronald Silver in this filing. The derivative summary is empty, indicating only a non-derivative acquisition of Class A Common Stock through a restricted stock unit award.